Figure 1.
Markov model.
Table 1.
Model inputs.
Table 2.
Expected Cost and QALYs in Base-case Analysis.
Figure 2.
One-way sensitivity analysis on incremental cost per quality-adjusted life-year (ICER) gained by dabigatran 150mg.
Figure 3.
Two-way sensitivity analyses on the cost-effectiveness of dabigatran 150mg versus genotype-guided anticoagulation care (AC).
Figure 4.
Variation in probability of each treatment option to be cost-effective against willingness-to-pay per QALY.